JP6820841B2 - ペグ化インターフェロンのための投薬計画 - Google Patents

ペグ化インターフェロンのための投薬計画 Download PDF

Info

Publication number
JP6820841B2
JP6820841B2 JP2017519649A JP2017519649A JP6820841B2 JP 6820841 B2 JP6820841 B2 JP 6820841B2 JP 2017519649 A JP2017519649 A JP 2017519649A JP 2017519649 A JP2017519649 A JP 2017519649A JP 6820841 B2 JP6820841 B2 JP 6820841B2
Authority
JP
Japan
Prior art keywords
interferon
weeks
treatment period
administered
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533192A (ja
JP2017533192A5 (enExample
Inventor
コーチュン リン
コーチュン リン
クリストフ クラーデ
クリストフ クラーデ
オレフ ザグリツェーチュク
オレフ ザグリツェーチュク
Original Assignee
ファーマエッセンティア コーポレイション
ファーマエッセンティア コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマエッセンティア コーポレイション, ファーマエッセンティア コーポレイション filed Critical ファーマエッセンティア コーポレイション
Publication of JP2017533192A publication Critical patent/JP2017533192A/ja
Publication of JP2017533192A5 publication Critical patent/JP2017533192A5/ja
Application granted granted Critical
Publication of JP6820841B2 publication Critical patent/JP6820841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2017519649A 2014-11-06 2015-11-06 ペグ化インターフェロンのための投薬計画 Active JP6820841B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192114.8 2014-11-06
EP14192114 2014-11-06
PCT/US2015/059410 WO2016073825A1 (en) 2014-11-06 2015-11-06 Dosage regimen for pegylated interferon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020151877A Division JP2021001184A (ja) 2014-11-06 2020-09-10 ペグ化インターフェロンのための投薬計画

Publications (3)

Publication Number Publication Date
JP2017533192A JP2017533192A (ja) 2017-11-09
JP2017533192A5 JP2017533192A5 (enExample) 2018-11-29
JP6820841B2 true JP6820841B2 (ja) 2021-01-27

Family

ID=51945707

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017519649A Active JP6820841B2 (ja) 2014-11-06 2015-11-06 ペグ化インターフェロンのための投薬計画
JP2020151877A Withdrawn JP2021001184A (ja) 2014-11-06 2020-09-10 ペグ化インターフェロンのための投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020151877A Withdrawn JP2021001184A (ja) 2014-11-06 2020-09-10 ペグ化インターフェロンのための投薬計画

Country Status (32)

Country Link
US (3) US11559567B2 (enExample)
EP (2) EP3215193B1 (enExample)
JP (2) JP6820841B2 (enExample)
KR (2) KR102724837B1 (enExample)
CN (1) CN107530403A (enExample)
AU (1) AU2015342908B2 (enExample)
BR (1) BR112017009193A2 (enExample)
CA (1) CA2964390A1 (enExample)
CL (1) CL2017001088A1 (enExample)
DK (1) DK3215193T3 (enExample)
EA (1) EA037151B1 (enExample)
ES (1) ES2966888T3 (enExample)
FI (1) FI3215193T3 (enExample)
HK (1) HK1243627A1 (enExample)
HR (1) HRP20231732T1 (enExample)
HU (1) HUE064909T2 (enExample)
IL (1) IL251627B (enExample)
LT (1) LT3215193T (enExample)
MX (1) MX389844B (enExample)
MY (1) MY191506A (enExample)
NZ (1) NZ730924A (enExample)
PH (1) PH12017500617B1 (enExample)
PL (1) PL3215193T3 (enExample)
PT (1) PT3215193T (enExample)
RS (1) RS65015B1 (enExample)
SG (1) SG11201702798PA (enExample)
SI (1) SI3215193T1 (enExample)
SM (1) SMT202400028T1 (enExample)
TW (1) TWI737583B (enExample)
UA (1) UA122867C2 (enExample)
WO (1) WO2016073825A1 (enExample)
ZA (1) ZA201702704B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134260A1 (en) * 2017-01-18 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
AU2022221496A1 (en) * 2021-08-29 2023-03-16 Pharmaessentia Corporation Method of Using Pegylated Interferon-alpha

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
RU2002105485A (ru) * 1999-08-13 2004-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
WO2001015736A2 (en) 1999-08-27 2001-03-08 Maxygen Aps Interferon-beta conjugates
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
OA13063A (en) 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BRPI0306993B8 (pt) 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
EP1546235B1 (en) 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
CA2547140A1 (en) 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
CN101010105A (zh) 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
US7365127B2 (en) 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP1869079A2 (en) 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
EP1834963A1 (en) 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
WO2008021487A1 (en) * 2006-08-18 2008-02-21 Pepgen Corporation Combination treatment method with interferon-tau
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
CA2698396C (en) 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN102131844B (zh) 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
UA109646C2 (uk) 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂

Also Published As

Publication number Publication date
MY191506A (en) 2022-06-28
PT3215193T (pt) 2023-12-15
EP3215193B1 (en) 2023-10-04
ZA201702704B (en) 2020-10-28
HRP20231732T1 (hr) 2024-03-15
WO2016073825A1 (en) 2016-05-12
DK3215193T3 (da) 2024-01-08
AU2015342908B2 (en) 2021-06-24
IL251627A0 (en) 2017-06-29
EP3215193A1 (en) 2017-09-13
KR20230079520A (ko) 2023-06-07
PH12017500617B1 (en) 2024-07-03
JP2017533192A (ja) 2017-11-09
CL2017001088A1 (es) 2018-01-12
KR20170083074A (ko) 2017-07-17
SI3215193T1 (sl) 2024-02-29
PH12017500617A1 (en) 2017-09-04
US11559567B2 (en) 2023-01-24
LT3215193T (lt) 2024-01-25
TW201618808A (zh) 2016-06-01
HUE064909T2 (hu) 2024-04-28
CA2964390A1 (en) 2016-05-12
EP4282485A3 (en) 2024-01-17
EP4282485A2 (en) 2023-11-29
UA122867C2 (uk) 2021-01-13
BR112017009193A2 (pt) 2018-01-30
AU2015342908A1 (en) 2017-05-04
CN107530403A (zh) 2018-01-02
RS65015B1 (sr) 2024-01-31
US20250186552A1 (en) 2025-06-12
IL251627B (en) 2021-12-01
US20170326206A1 (en) 2017-11-16
SMT202400028T1 (it) 2024-03-13
US20230131552A1 (en) 2023-04-27
MX2017005244A (es) 2017-08-18
EP3215193A4 (en) 2018-07-25
PL3215193T3 (pl) 2024-03-18
EA201790991A1 (ru) 2017-11-30
HK1243627A1 (zh) 2018-07-20
MX389844B (es) 2025-03-04
EA037151B1 (ru) 2021-02-11
FI3215193T3 (fi) 2023-12-28
US12343381B2 (en) 2025-07-01
KR102540109B1 (ko) 2023-06-02
NZ730924A (en) 2022-04-29
ES2966888T3 (es) 2024-04-24
JP2021001184A (ja) 2021-01-07
KR102724837B1 (ko) 2024-10-31
SG11201702798PA (en) 2017-05-30
TWI737583B (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
US12343381B2 (en) Dosage regimen for pegylated interferon
TWI241913B (en) Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
ES2417061T3 (es) Formulaciones líquidas de interferón estabilizadas, exentas de hsa
CN104826094A (zh) 包含增效比例的干扰素γ和α的稳定的制剂
JP2003525907A (ja) Ｈｉｖ免疫アジュバント治療
ES2666850T3 (es) Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida
ES2319777T3 (es) Tratamiento de carcinoma de celulas renales.
ES2991384T3 (es) Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C)
JP2013543872A (ja) インターフェロン−βの安定に保存される組成物
ES3009748T3 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
WO2016048189A1 (ru) Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
TWI271196B (en) CML therapy
US20070154454A1 (en) Compositions and methods for treating poxvirus infection
ES2319776T3 (es) Terapia de melanoma.
WO2014130811A1 (en) Interferon beta formulation
CN104136038A (zh) 体腔积液抑制剂
CN114028544A (zh) 一种动员淋巴瘤和骨髓瘤干细胞的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170531

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200910

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201005

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210105

R150 Certificate of patent or registration of utility model

Ref document number: 6820841

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250